Facilitators and Barriers in Implementing Buprenorphine in the Veterans Health Administration

Psychology of Addictive Behaviors

Volumn 25, Issue 2, 2011, Pages 215-224

  Gordon, Adam J ^a,b   Kavanagh, Greg ^a   Krumm, Margaret ^a   Ramgopal, Rajeev ^a   Paidisetty, Sanjay ^b   Aghevli, Minu ^a   Goodman, Francine ^c   Trafton, Jodie ^d,e   Liberto, Joseph ^a,f  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Buprenorphine; Opioid related disorders; United States Department of Veterans Affairs

Indexed keywords

BUPRENORPHINE;

ARTICLE; ATTITUDE TO HEALTH; GOVERNMENT; HEALTH CARE FACILITY; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HUMAN; OPIATE ADDICTION; PRESCRIPTION; PREVALENCE; SEMI STRUCTURED INTERVIEW; STIGMA; TELEPHONE; THEORY;

ATTITUDE OF HEALTH PERSONNEL; BUPRENORPHINE; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS HEALTH;

EID: 79959285218     PISSN: 0893164X     EISSN: 19391501     Source Type: Journal    
DOI: 10.1037/a0022776     Document Type: Article

References (34)

1. Alford D.P., LaBelle C.T., Richardson J.M., O'Connell J.J., Hohl C.A., Cheng D.M., Samet J.H. Treating homeless opioid dependent patients with buprenorphine in an office-based setting. Journal of General Internal Medicine 2007, 22:171-176.
2. Barnett P.G. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction 2009, 104:982-992.
3. Barry D.T., Irwin K.S., Jones E.S., Becker W.C., Tetrault J.M., Sullivan L.E., Fiellin D.A. Integrating buprenorphine treatment into office-based practice: A qualitative study. Journal of General Internal Medicine 2009, 24:218-225.
4. Basu S., Smith-Rohrberg D., Bruce R.D., Altice F.L. Models for integrating buprenorphine therapy into the primary HIV care setting. Clinical Infectious Diseases 2006, 42:716-721.
5. Dalton A., Saweikis M., McKellar J.D. Health services for VA substance use disorder patients 2006, Comparison of utilization in fiscal years 2005, 2004, 2003, and 2002. Retrieved from http://www.chce.research.med.va.gov/pdf/2005Yellowbook.pdf.
6. Damschroder L.J., Aron D.C., Keith R.E., Kirsh S.R., Alexander J.A., Lowery J.C. Fostering implementation of health services research findings into practice: A consolidated framework for advancing implementation science. Implementation Science 2009, 4:50.
7. VA/DoD Clinical practice guideline for management of substance use disorders (SUD) 2009, Department of Veterans Affairs and Department of Defense, Retrieved from http://www.healthquality.va.gov/sud/sud_full_601f.pdf.
8. Uniform mental health services in VA medical centers and clinics 2009, Department of Veterans Affairs, Veterans Health Administration, Retrieved from http://www.va.gov/vhapublications/ViewPublication.asp?pub_ID=1762.
9. Fiellin D.A., Moore B.A., Sullivan L.E., Becker W.C., Pantalon M.V., Chawarski M.C., Schottenfeld R.S. Long-term treatment with buprenorphine/naloxone in primary care: Results at 2-5 years. American Journal On Addictions 2008, 17:116-120.
10. Fiellin D.A., O'Connor P.G. Office-based treatment of opioid dependent patients. New England Journal of Medicine 2002, 347:339-345.
11. Fiellin D.A., Pantalon M.V., Chawarski M.C., Moore B.A., Sullivan L.E., O'Connor P.G., Schottenfeld R.S. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. New England Journal of Medicine 2006, 355:365-374.
12. Fudala P.J., Bridge T.P., Herbert S., Williford W.O., Chiang C.N., Jones K., Tusel D. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine 2003, 349:949-958.
13. Goodman F., Gordon A., Kivlahan D., Dalack G., McNicholas L., Oslin D., Suchinsky R. Criteria for use of buprenorphine/naloxone and Buprenorphine sublingual tablets 2006, Retrieved from http://www.pbm.va.gov/criteria/BuprenorphineCriteriaForUse.pdf.
14. Gordon A.J., Geppert C.M.A., Saxon A., Cotton A., Bondurant T., Acquaviva M.P., Trafton J. Models for implementing buprenorphine treatment in the VHA. Federal Practitioner 2009, 26:48-57.
15. Gordon A.J., Liberto J., Granda S., Salmon-Cox S., Andree T., McNicholas L. Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration. American Journal On Addictions 2008, 17:459-462.
16. Gordon A.J., Liberto J., Granda S., Salmon-Cox S., Andrée T., McNicholas L. Physician training is never a failure. American Journal of Addiction 2009, 18:337-338.
17. Gordon A.J., Trafton J.A., Saxon A.J., Gifford A.L., Goodman F., Calabrese V.S., Liberto J. Implementation of buprenorphine in the Veterans Health Administration: Results of the first 3 years. Drug and Alcohol Dependence 2007, 90:292-296.
18. Gunderson E.W., Fiellin D.A., Levin F.R., Sullivan L.E., Kleber H.D. Evaluation of a combined online and in person training in the use of buprenorphine. Substance Abuse 2006, 27:39-45.
19. Harris A.H., Gospodarevskaya E., Ritter A.J. A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics 2005, 23:77-91.
20. Jones E.S., Moore B.A., Sindelar J.L., O'Connor P.G., Schottenfeld R.S., Fiellin D.A. Cost analysis of clinic and office-based treatment of opioid dependence: Results with methadone and buprenorphine in clinically stable patients. Drug and Alcohol Dependence 2009, 99:132-140.
21. Krantz M.J., Mehler P.S. Treating opioid dependence. Growing implications for primary care. Archives of Internal Medicine 2004, 164:277-288.
22. Mark T.L., Woody G.E., Juday T., Kleber H.D. The economic costs of heroin addiction in the United States. Drug and Alcohol Dependence 2001, 61:195-206.
23. Marsch L.A. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: A meta-analysis. Addiction 1998, 93:515-532.
24. Mattick R.P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence 2009, Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD002209.
25. McKellar J.D., Saweikis M. Health services for VA substance use disorder patients: Comparison of utilization in fiscal years 2004, 2003, and 1998 2005, Program Evaluation and Resource Center and HSR&D Center for Health Care Evaluation, VA Palo Alto Health Care System, Palo Alto, CA.
26. McQueen L., Mittman B.S., Demakis J.G. Overview of the Veterans Health Administration (VHA) Quality Enhancement Research Initiative (QUERI). Journal of the American Medical Informatics Association 2004, 11:339-343.
27. Effective medical treatment of opiate addiction. Journal of the American Medical Association 1998, 280:1936-1943. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction.
28. Policy paper: Opioid agonist treatment 1999, Office of National Drug Control Policy, Author, Washington, DC.
29. Parran T.V., Adelman C.A., Merkin B., Pagano M.E., Defranco R., Ionescu R.A., Mace A.G. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug and Alcohol Dependence 2010, 106:56-60.
30. Raisch D.W., Fye C.L., Boardman K.D., Sather M.R. Opioid dependence treatment, including buprenorphine/naloxone. Annals of Pharmacotherapy 2002, 36:312-321.
31. Stein M.D., Cioe P., Friedmann P.D. Buprenorphine retention in primary care. Journal of General Internal Medicine 2005, 20:1038-1041.
32. Stetler C.B., Legro M.W., Wallace C.M., Bowman C., Guihan M., Hagedorn H., Smith J.L. The role of formative evaluation in implementation research and the QUERI experience. Journal of General Internal Medicine 2006, 21:S1-S8.
33. Sullivan L.E., Moore B.A., Chawarski M.C., Pantalon M.V., Barry D., O'Connor P.G., Fiellin D.A. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. Journal of Substance Abuse Treatment 2008, 35:87-92.
34. Walley A.Y., Alperen J.K., Cheng D.M., Botticelli M., Castro-Donlan C., Samet J.H., Alford D.P. Office-based management of opioid dependence with buprenorphine: Clinical practices and barriers. Journal of General Internal Medicine 2008, 23:1393-1398.